Could be worse, you could own Favrille

Favrille, Inc. (NASDAQ:FVRL) fell 85% today, shares are now only 25 cents after the Biopharmaceutical said it will end development of Specifid, after the drug failed to prove effective against non-Hodgkin's lymphoma in a late-stage trial.  Major swing, and a miss.

More from Forbes.com:

Favrille (nasdaq: FVRL) said patients taking Specifid and Bayer (nyse: BAY) AG's Leukine did not show slower progression of the immune system cancer than patients taking Leukine and a placebo. All patients in the trial had previously taken Genentech (nyse: DNA)'s Rituxan.

"We are clearly very disappointed with the data from this trial," said John P. Longenecker, president and chief executive of Favrille, in a statement. "Based on these results, we are discontinuing development of Specifid and are currently evaluating steps to conserve cash and recognize value on our assets."

Masters, think twice if you think there's a bounce play in this stock, you can't bounce a dead cat.

 We believe that today's investment newsletters are overpriced and do not provide investors with the information they need to protect their investments. Why should a subscription to a financial newsletter cost more than Maxim?  It shouldn't, we are able to charge a low price thanks to offsetting the costs with advertising and pass the savings on to our subscribers.

 But how much does it cost? Master Picks newsletter is only $9 a Year.

That's 12 issues for an entire year for only $9. 

On sale, only at WallStNewsletters.com.  Home of the FULL MONTE.  A portal designed to only contain paid financial content.

What are you waiting for? Sign up now!